In Vivo Resistance to CeftolozaneTazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways
Joint Authors
Skoglund, Erik
Abodakpi, Henrietta
Rios, Rafael
Diaz, Lorena
De La Cadena, Elsa
Dinh, An Q.
Ardila, Javier
Miller, William R.
Munita, Jose M.
Arias, Cesar A.
Tam, Vincent H.
Tran, Truc T.
Source
Case Reports in Infectious Diseases
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-12-23
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
Two pairs of ceftolozane/tazobactam susceptible/resistant P.
aeruginosa were isolated from 2 patients after exposure to β-lactams.
The genetic basis of ceftolozane/tazobactam resistance was evaluated, and β-lactam-resistant mechanisms were assessed by phenotypic assays.
Whole genome sequencing identified mutations in AmpC including the mutation (V213A) and a deletion of 7 amino acids (P210–G216) in the Ω-loop.
Phenotypic assays showed that ceftolozane/tazobactam resistance in the strain with AmpCV213A variant was associated with increased β-lactamase hydrolysis activity.
On the other hand, the deletion of 7 amino acids in the Ω-loop of AmpC did not display enhanced β-lactamase activity.
Resistance to ceftolozane/tazobactam in P.
aeruginosa is associated with changes in AmpC; however, the apparent loss of β-lactamase activity in AmpC∆7 suggests that non-AmpC mechanisms could play an important role in resistance to β-lactam/β-lactamase inhibitor combinations.
American Psychological Association (APA)
Skoglund, Erik& Abodakpi, Henrietta& Rios, Rafael& Diaz, Lorena& De La Cadena, Elsa& Dinh, An Q.…[et al.]. 2018. In Vivo Resistance to CeftolozaneTazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways. Case Reports in Infectious Diseases،Vol. 2018, no. 2018, pp.1-4.
https://search.emarefa.net/detail/BIM-1144696
Modern Language Association (MLA)
Skoglund, Erik…[et al.]. In Vivo Resistance to CeftolozaneTazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways. Case Reports in Infectious Diseases No. 2018 (2018), pp.1-4.
https://search.emarefa.net/detail/BIM-1144696
American Medical Association (AMA)
Skoglund, Erik& Abodakpi, Henrietta& Rios, Rafael& Diaz, Lorena& De La Cadena, Elsa& Dinh, An Q.…[et al.]. In Vivo Resistance to CeftolozaneTazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways. Case Reports in Infectious Diseases. 2018. Vol. 2018, no. 2018, pp.1-4.
https://search.emarefa.net/detail/BIM-1144696
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1144696